載入...
ErbB activation signatures as potential biomarkers for anti-ErbB3 treatment in HNSCC
Head and neck squamous cell carcinoma (HNSCC) accounts for 3–5% of all tumor types and remains an unmet medical need with only two targeted therapies approved to date. ErbB3 (HER3), the kinase-impaired member of the EGFR/ErbB family, has been implicated as a disease driver in a number of solid tumor...
Na minha lista:
| 發表在: | PLoS One |
|---|---|
| Main Authors: | , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Public Library of Science
2017
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5517012/ https://ncbi.nlm.nih.gov/pubmed/28723928 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0181356 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|